Efgartigimod
argenx
[]
4/ phase 3 trial efgartigimod (targeting fcrn and lowering total igg levels, n=86) vs placebo (n=45) in primary immune thrombocytopenia demonstrates the clinical and analytical (platelet count) improvement with efgartigimod by dr catherine m broome #ash22 
Medical degree at @USAL | Internal Medicine student at @HematoCAUSA | Hematology and Hemotherapy at Hospital Ramón y Cajal @HematoRYC | PhD student at @UAHes